相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial
Byeong-Keuk Kim et al.
LANCET (2022)
Projected impact of treatment intensification with statin, ezetimibe, and statin plus ezetimibe fixed-dose combination on MACE across six countries
Michel Farnier et al.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2022)
Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel
Jan Boren et al.
EUROPEAN HEART JOURNAL (2020)
Pharmacokinetics and bioequivalence of a rosuvastatin/ezetimibe fixed-dose combination tablet versus single agents in healthy male subjects
Woo Youl Kang et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2018)
A Phase III, Multicenter, Randomized, Double-blind, Active Comparator Clinical Trial to Compare the Efficacy and Safety of Combination Therapy With Ezetimibe and Rosuvastatin Versus Rosuvastatin Monotherapy in Patients With Hypercholesterolemia: I-ROSETTE (Ildong Rosuvastatin & Ezetimibe for Hypercholesterolemia) Randomized Controlled Trial
Soon Jun Hong et al.
CLINICAL THERAPEUTICS (2018)
Epidemiology of Dyslipidemia in the Asia Pacific Region
Chao-Feng Lin et al.
INTERNATIONAL JOURNAL OF GERONTOLOGY (2018)
Pharmacokinetic and pharmacodynamic interaction between ezetimibe and rosuvastatin in healthy male subjects
Chang Hee Kim et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2017)
Combination Therapy of Rosuvastatin and Ezetimibe in Patients with High Cardiovascular Risk
Young-June Yang et al.
CLINICAL THERAPEUTICS (2017)
Comparison of Pharmacokinetics and Safety of a Fixed-dose Combination of Rosuvastatin and Ezetimibe Versus Separate Tablets in Healthy Subjects
Kyoung Lok Min et al.
CLINICAL THERAPEUTICS (2017)
Estimating the future burden of cardiovascular disease and the value of lipid and blood pressure control therapies in China
Warren Stevens et al.
BMC HEALTH SERVICES RESEARCH (2016)
Effect of fixed-dose combinations of ezetimibe plus rosuvastatin in patients with primary hypercholesterolemia: MRS-ROZE (Multicenter Randomized Study of ROsuvastatin and eZEtimibe)
Kyung-Jin Kim et al.
CARDIOVASCULAR THERAPEUTICS (2016)
Combine and conquer: advantages and disadvantages offixed-dose combination therapy
D. S. H. Bell
DIABETES OBESITY & METABOLISM (2013)
Hyperlipidemia as a Risk Factor for Cardiovascular Disease
Robert H. Nelson
PRIMARY CARE (2013)
Lowering Plasma Cholesterol by Raising LDL Receptors - Revisited
Stephen G. Young et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety and Efficacy of Ezetimibe Added on to Rosuvastatin 5 or 10 mg Versus Up-Titration of Rosuvastatin in Patients With Hypercholesterolemia (the ACTE Study)
Harold E. Bays et al.
AMERICAN JOURNAL OF CARDIOLOGY (2011)
Population pharmacokinetics of rosuvastatin: implications of renal impairment, race, and dyslipidaemia
Tsang-Bin Tzeng et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment
E Lee et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Pharmacodynamic interaction between ezetimibe and rosuvastatin
T Kosoglou et al.
CURRENT MEDICAL RESEARCH AND OPINION (2004)
分享论文
